<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04608292</url>
  </required_header>
  <id_info>
    <org_study_id>023-2020</org_study_id>
    <nct_id>NCT04608292</nct_id>
  </id_info>
  <brief_title>Measuring Fluid Flow in the Brain Using Alcohol and MRI in Healthy Participants</brief_title>
  <official_title>Quantitative Measurement of Intracranial Interstitial Fluid Flow Using Magnetic Resonance Spectroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intracranial interstitial fluid (ISF) flow is crucial for adequate clearance of extracellular&#xD;
      waste products from the brain parenchyma. Recent demonstrations have shown that a deficiency&#xD;
      in flow leads to the accumulation of such waste products in neurodegenerative disorders.&#xD;
      Unfortunately, no clinical investigation that gives a quantitative measure of ISF flow&#xD;
      exists. Such a test could prove very useful in the clinical setting for multiple neurologic&#xD;
      disorders by providing a measure of potential diagnostic importance, as well as yielding a&#xD;
      means to monitor response to treatment.&#xD;
&#xD;
      The investigators hypothesize that such an investigation can be developed using magnetic&#xD;
      resonance spectroscopy to give a quantitative measure of ISF flow, using spectroscopy of&#xD;
      ethanol as a dynamic marker of interstitial fluid. Beneficially, the approach is&#xD;
      non-invasive. This pilot project aims to develop this technique with proof of concept in&#xD;
      healthy volunteers (males in the age range of 20-75).&#xD;
&#xD;
      This pilot project aims to develop the technique, demonstrating its ability to detect ISF&#xD;
      flow and potential differences in rates among healthy volunteers. Success at this stage will&#xD;
      give rise to this technique being extended to studies involving individuals with various&#xD;
      forms of intracranial pathology for comparison with values seen in healthy individuals, with&#xD;
      the ultimate goal of it providing a measure of diagnostic significance in multiple clinical&#xD;
      scenarios.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study hypothesis:&#xD;
&#xD;
      Intracranial interstitial fluid (ISF) flow is crucial for adequate clearance of extracellular&#xD;
      waste products from the brain parenchyma. Recent demonstrations have shown that its&#xD;
      deficiency leads to their accumulation in neurodegenerative disorders. The hypothesis of this&#xD;
      project is MRS and/or MTI can be used to give a quantitative measure of intracranial&#xD;
      interstitial fluid flow.&#xD;
&#xD;
      Goals:&#xD;
&#xD;
      The primary goal is to provide a quantitative measure of ISF flow rate through the brain&#xD;
      parenchyma. This will be performed by making multiple measurements of the characteristic&#xD;
      ethanol peak at different time points with MRS or ethanol-related decreases in water&#xD;
      saturation signal in MTI, following its ingestion. This will allow the transit of ethanol,&#xD;
      which is equal to the transit of ISF, to be obtained and reported using common transport&#xD;
      parameters such as time-to-peak (TTP) and mean transit time (MTT).&#xD;
&#xD;
      Secondary objectives include determining a range of values that may be considered normal&#xD;
      ranges for ISF flow rates in healthy individuals. This will be helpful in future experiments&#xD;
      when such values will be compared with rates measuring for individuals with various different&#xD;
      types of intracranial pathology.&#xD;
&#xD;
      INVESTIGATION STUDY DESIGN:&#xD;
&#xD;
      This pilot project will be experimental with the aim of determining the best quantitative&#xD;
      criteria from ethanol MRS or MTI labeling of intracranial ISF flow data to give a reliable&#xD;
      clearance metric. To achieve this, the initial proof of concept study will involve 10 healthy&#xD;
      male volunteers between the ages of 20-75 undergoing the ethanol-MRS or MTI protocol. This&#xD;
      work will be quantitative in nature, since discrete MR signals will be measured and analyzed.&#xD;
&#xD;
      Data Collection Study participants will be required to have fasted a minimum of 6 hours prior&#xD;
      to initiating the experiment and refrained from alcohol ingestion for 12 hours. A quick&#xD;
      screen will be performed by a research team member of the participant's medications, alcohol&#xD;
      consumption, and any neurological conditions prior to moving forward with the examination to&#xD;
      verify all volunteers meet all inclusion criteria for the study.&#xD;
&#xD;
      Data will be acquired using either magnetic resonance spectroscopy (MRS), magnetic resonance&#xD;
      spectroscopic imaging (MRSI), or magnetization transfer imaging (MTI). A relatively short&#xD;
      acquisition (5-7 minutes) will be repeated to acquire a time course for ethanol transit&#xD;
      through the brain.&#xD;
&#xD;
      Each study participant will undergo pre-ethanol ingestion MR acquisition. The volunteer will&#xD;
      then be given an ethanol-containing beverage. The ethanol content will be approximately 0.5&#xD;
      g/kg, mixed in 355 mL of a non-caffeinated, sugar-free carbonated drink as done previously in&#xD;
      other human ethanol MRS experiments (7). The drink must be consumed within 5 minutes and may&#xD;
      be provided through clear plastic tubing so the subject does not have to be removed from the&#xD;
      scanner. Blood alcohol concentration (BAC) levels for this work are not expected to exceed&#xD;
      0.05%, considered a low level, at the end of the experiment.&#xD;
&#xD;
      After consuming the ethanol-containing beverage, scout images will be acquired again to&#xD;
      re-localize the voxels for each subsequent spectral image if study participants need to be&#xD;
      placed back in the MR scanner (ie. did not ingest ethanol through tubing). MRS, MRSI, or MTI&#xD;
      will be performed at ~5-7 minutes/spectrum or image, repeating the process continuously for&#xD;
      60-90 minutes. During the scanning, the patient may be asked to breathe through the&#xD;
      ClearMateTM, a specially designed, MR-compatible non-rebreathing circuit that provides oxygen&#xD;
      and carbon dioxide that quickly decreases a person's blood alcohol level.&#xD;
&#xD;
      After the final acquisition, the patient will be taken to a supervised area where he/she will&#xD;
      remain until blood ethanol levels are registered below 0.05% via a standard breathalyzer&#xD;
      test. Once the participant has met this requirement and state that they feel safe to leave&#xD;
      the premises, they will be free to go within the recommendations of the study and their&#xD;
      participation considered to be complete. Breath sampling will be performed at 30-minute&#xD;
      intervals if it is still high.&#xD;
&#xD;
      Finally, since the most accurate way to assess the blood alcohol kinetics is by making&#xD;
      comparisons of arterial and venous blood levels, peripheral arterial lines will be inserted&#xD;
      (by a Sunnybrook staff anesthesiologist) in a few select study participants. Periodic&#xD;
      arterial blood samples from these individuals will be measured for the blood alcohol content&#xD;
      and compared with the values for blood samples drawn concurrently from the peripheral&#xD;
      intravenous line.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The study will begin with the simplest imaging measurements, and only proceed to longer or more complicated measurements if necessary. Re-breathing apparatus will be used only once the imaging measurement has been decided upon, and blood sampling will be used only on a few subjects to confirm the results. Thus, while there are 9 arms to this trial, it is possible that as few as 3 arms will actually be used.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intracranial Interstitial Fluid Flow Rate</measure>
    <time_frame>Within 1 week of actual measurement</time_frame>
    <description>The calculated flow rate of intracranial interstitial fluid and its standard deviation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood alcohol levels</measure>
    <time_frame>Within 1 week of blood samples</time_frame>
    <description>Level of alcohol in venous and arterial blood during the examination</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Diagnostic Technics, Neurological</condition>
  <arm_group>
    <arm_group_label>Single-voxel MRS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MRS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multi-voxel MRSI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MRSI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnetization Transfer Imaging</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MTI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single-voxel MRS + ClearMate(TM)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MRS+CM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multi-voxel MRSI + ClearMate(TM)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MRSI+CM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnetization Transfer Imaging + ClearMate(TM)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MTI+CM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single-voxel MRS + CM + Blood Sampling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MRS+CM+B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multi-voxel MRSI + CM + Blood Sampling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MRSI+CM+B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnetization Transfer Imaging + CM + Blood Sampling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MTI+CM+B</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Single-voxel MRS</intervention_name>
    <description>Diagnostic test is a single voxel MRS scan</description>
    <arm_group_label>Single-voxel MRS</arm_group_label>
    <arm_group_label>Single-voxel MRS + CM + Blood Sampling</arm_group_label>
    <arm_group_label>Single-voxel MRS + ClearMate(TM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Multi-voxel MRSI</intervention_name>
    <description>Diagnostic test is a multi-voxel MRS imaging scan</description>
    <arm_group_label>Multi-voxel MRSI</arm_group_label>
    <arm_group_label>Multi-voxel MRSI + CM + Blood Sampling</arm_group_label>
    <arm_group_label>Multi-voxel MRSI + ClearMate(TM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Magnetization Transfer Imaging</intervention_name>
    <description>Diagnostic test is a set of magnetic transfer weighted images</description>
    <arm_group_label>Magnetization Transfer Imaging</arm_group_label>
    <arm_group_label>Magnetization Transfer Imaging + CM + Blood Sampling</arm_group_label>
    <arm_group_label>Magnetization Transfer Imaging + ClearMate(TM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Alcohol ingestion</intervention_name>
    <description>Participants will ingest an ethanol-containing beverage of approximately 0.5g/kg of ethanol mixed in 355 mL of a non-caffeinated, sugar-free carbonated drink which must be consumed in 5 minutes</description>
    <arm_group_label>Magnetization Transfer Imaging</arm_group_label>
    <arm_group_label>Magnetization Transfer Imaging + CM + Blood Sampling</arm_group_label>
    <arm_group_label>Magnetization Transfer Imaging + ClearMate(TM)</arm_group_label>
    <arm_group_label>Multi-voxel MRSI</arm_group_label>
    <arm_group_label>Multi-voxel MRSI + CM + Blood Sampling</arm_group_label>
    <arm_group_label>Multi-voxel MRSI + ClearMate(TM)</arm_group_label>
    <arm_group_label>Single-voxel MRS</arm_group_label>
    <arm_group_label>Single-voxel MRS + CM + Blood Sampling</arm_group_label>
    <arm_group_label>Single-voxel MRS + ClearMate(TM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ClearMate</intervention_name>
    <description>Participants will breathe through the ClearMate, an MR-compatible non-rebreathing circuit which provides oxygen and carbon dioxide that quickly decreases a person's blood alcohol level.</description>
    <arm_group_label>Magnetization Transfer Imaging + CM + Blood Sampling</arm_group_label>
    <arm_group_label>Magnetization Transfer Imaging + ClearMate(TM)</arm_group_label>
    <arm_group_label>Multi-voxel MRSI + CM + Blood Sampling</arm_group_label>
    <arm_group_label>Multi-voxel MRSI + ClearMate(TM)</arm_group_label>
    <arm_group_label>Single-voxel MRS + CM + Blood Sampling</arm_group_label>
    <arm_group_label>Single-voxel MRS + ClearMate(TM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Participants will have a peripheral arterial and peripheral venous line inserted and periodic arterial and venous blood samples will be measured for blood alcohol content.</description>
    <arm_group_label>Magnetization Transfer Imaging + CM + Blood Sampling</arm_group_label>
    <arm_group_label>Multi-voxel MRSI + CM + Blood Sampling</arm_group_label>
    <arm_group_label>Single-voxel MRS + CM + Blood Sampling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to consent, effectively communicate with the investigator, and comply with&#xD;
             study protocols&#xD;
&#xD;
          -  Low consumer of ethanol (less than 6 drinks per week where a drink is 1 oz of&#xD;
             distilled spirits, 6 oz wine, 12 oz beer)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to MRI&#xD;
&#xD;
          -  History of alcohol or substance abuse&#xD;
&#xD;
          -  History of liver pathology&#xD;
&#xD;
          -  Currently taking medication such as metronidazole which could induce a disulfiram&#xD;
             reaction with ethanol&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Greg J Stanisz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Mikulis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Krembil Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sunnybrook Research Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Oakden, PhD</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>89916</phone_ext>
      <email>wendy.oakden@sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <last_name>Bharathy Lingamoorthy</last_name>
      <phone>416-480-4293</phone>
      <email>bharathy.lingamoorthy@sunnybrook.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Jesse M Klostranec, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 23, 2020</study_first_submitted>
  <study_first_submitted_qc>October 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

